Advanced search
Publication Cover
Hematology Volume 24, 2019 - Issue 1
Submit an article Journal homepage
2,821
Views
2
CrossRef citations to date
0
Altmetric
Articles

A triplex probe-based TaqMan qPCR assay for Calreticulin type I and II mutation detection

Yigui TangDepartment of Laboratory Medicine, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China
,
Changgen ShiChina National Population and Family Planning Key Laboratory of Contraceptive Drugs and Device, Shanghai Institute of Planned Parenthood Research(SIPPR), Shanghai, People’s Republic of China;School of Life Sciences, Fudan University, Shanghai, People’s Republic of China
,
Zhiyuan WuDepartment of Laboratory Medicine, Huashan Hospital North, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China
,
Ni FanDepartment of Hematology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China
,
Xiao XuDepartment of Central Laboratory, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China
,
Zhihua KangDepartment of Laboratory Medicine, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China
,
Xinju ZhangDepartment of Central Laboratory, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China
,
Weizhe MaDepartment of Central Laboratory, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China
&
Ming GuanDepartment of Laboratory Medicine, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China;Department of Central Laboratory, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of ChinaCorrespondence[email protected]
 show all
Pages 26-31 | Published online: 06 Aug 2018

References

  • Cahu X, Constantinescu SN. Oncogenic drivers in myeloproliferative neoplasms: from JAK2 to calreticulin mutations. Curr Hematol Malig Rep. 2015;10:335–343. doi: 10.1007/s11899-015-0278-x
  • Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369:2391–2405. doi: 10.1056/NEJMoa1312542
  • Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369:2379–2390. doi: 10.1056/NEJMoa1311347
  • Lu YC, Weng WC, Lee H. Functional roles of calreticulin in cancer biology. Biomed Res Int. 2015;2015:526524.
  • Tefferi A, Thiele J, Vannucchi AM, et al. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia. 2014;28:1407–1413. doi: 10.1038/leu.2014.35
  • Tefferi A, Wassie EA, Guglielmelli P, et al. Type 1 versus type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. Am J Hematol. 2014;89:E121–E124. doi: 10.1002/ajh.23743
  • Rotunno G, Pacilli A, Artusi V, et al. Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group. Am J Hematol. 2016;91:681–686. doi: 10.1002/ajh.24377
  • Verger E, Cassinat B, Chauveau A, et al. Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations. Blood. 2015;126:2585–2591. doi: 10.1182/blood-2015-07-659060
  • Yao QM, Zhou J, Gale RP, et al. A rapid, highly accurate method for quantifying CALR mutant allele burden in persons with myeloproliferative neoplasms. Hematology. 2015;20:517–522. doi: 10.1179/1607845415Y.0000000009
  • Chi J, Manoloukos M, Pierides C, et al. Calreticulin mutations in myeloproliferative neoplasms and new methodology for their detection and monitoring. Ann Hematol. 2015;94:399–408. doi: 10.1007/s00277-014-2232-8
  • Wu Z, Zhang X, Xu X, et al. The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms. J Hematol Oncol. 2014;7:372.
  • Passamonti F, Maffioli M. Update from the latest WHO classification of MPNs: a user’s manual. Hematol Am Soc Hematol Educ Program. 2016;2016:534–542.
  • Passamonti F, Giorgino T, Mora B, et al. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia. 2017;31(12):2726–2731. doi: 10.1038/leu.2017.169
  • Van der Velden V, Hochhaus A, Cazzaniga G, et al. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia. 2003;17(6):1013–1034. doi: 10.1038/sj.leu.2402922
  • Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124:2507–2513. quiz 2615. doi: 10.1182/blood-2014-05-579136
  • Barosi G, Massa M, Campanelli R, et al. Primary myelofibrosis: older age and high JAK2V617F allele burden are associated with elevated plasma high-sensitivity C-reactive protein levels and a phenotype of progressive disease. Leuk Res. 2017;60:18–23. doi: 10.1016/j.leukres.2017.06.004
  • Bilbao-Sieyro C, Santana G, Moreno M, et al. High resolution melting analysis: a rapid and accurate method to detect CALR mutations. PLoS One. 2014;9:e103511. doi: 10.1371/journal.pone.0103511
  • Chi J, Nicolaou KA, Nicolaidou V, et al. Calreticulin gene exon 9 frameshift mutations in patients with thrombocytosis. Leukemia. 2014;28:1152–1154. doi: 10.1038/leu.2013.382
  • Jones AV, Ward D, Lyon M, et al. Evaluation of methods to detect CALR mutations in myeloproliferative neoplasms. Leuk Res. 2015;39:82–87. doi: 10.1016/j.leukres.2014.11.019
  • Loeb LA, Loeb KR, Anderson JP. Multiple mutations and cancer. Proc Natl Acad Sci U S A. 2003;100:776–781. doi: 10.1073/pnas.0334858100
  • Bench AJ, White HE, Foroni L, et al. Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations. Br J Haematol. 2013;160:25–34. doi: 10.1111/bjh.12075

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.